Accumulating evidence suggests that prestroke statin therapy could improve functional recovery following acute ischemic stroke. A recent meta-analysis of previous findings and a new study support this suggestion. These findings should, however, be interpreted with caution owing to possible publication bias favoring small studies with positive results.
Thus, consider able interest has been shown in finding other agents to improve functional status after ischemic stroke. Preclinical data suggest that use of statins before stroke occurs could improve subsequent functional outcomes, through mechanisms including promotion of angiogenesis and neuro genesis, improvement in blood flow, and modification of inflammatory and coagulation pathways. 3 Statins are readily available and are well-tolerated by most patients, further increasing the attractiveness of these agents.
Previously published reports on the effects of prestroke statin treatment on functional recovery after acute ischemic stroke have usually been limited by small sample sizes, heterogeneous choices for the definition of a good functional outcome, and potential publication bias in favor of positive studies. To address these issues, Biffi et al. at the Massachusetts General Hospital have used their single-center experience and performed a meta-analysis of 11 previously published studies. 4 In the first part of their study, the researchers investigated the effect of antecedent statins on functional outcome in patients who arrived at the institution within 24 h of the onset of symptoms of acute ischemic stroke. A good functional outcome was defined as a modified Rankin Scale score of 0-2. Among a total of 893 patients, 126 were receiving statin therapy at the time of their presentation; these patients were more likely to have hyperlipidemia and/or a history of antihypertensive medication use, tobacco use, or alcohol consumption than patients who were not being treated with statins. Treatment with statins before stroke onset was not associated with favorable functional outcome at 90 days or improved mortality. In prespecified analyses that distinguished among stroke etiologies, statins were associated with improved outcomes among the 102 patients with small-vessel disease (odds ratio [OR] 1.97, 95% CI 1.02-3.79), although only 10 of these patients were taking statins. This finding highlights the potential value of statin use among patients with stroke etiologies other than large-artery atherosclerosis, even though patients with large-artery athero sclerosis might be expected to benefit most from statins.
In the meta-analysis, Biffi et al. combined the above study data with 11 pre vious publications, including single-center experi ences, population-based studies and one clinical trial (the Stroke Prevention by Aggres sive Reduction in Cholesterol Levels [SPARCL] study). Although patients in clini cal trials may differ from unselected patients, 5 the results from the SPARCL study were broadly similar to those from the observational cohorts. The meta-analysis was conducted on data from a total of 2,013 patients receiving statins and 9,682 patients not receiving statins. The investigators found that antecedent statin treatment was associated with improved functional outcomes for all ische mic strokes (OR 1.62, 95% CI 1.39-1.88), as well as in subtype meta-analyses of strokes with large-artery and small-vessel etiologies.
The investigators cautioned against drawing definite conclusions from their metaanalysis, and their subsequent bias analysis was particularly informative. A so-called small-study effect-whereby the smallest studies tend to show the largest effect sizes-was suspected and proven. Through accepted statistical techniques, the researchers also found evidence for publication bias, such that studies with negative results tended not to be published. Despite these caveats, the researchers concluded that their results suggested a possible associ ation between statin use before stroke and improved function al outcome.
The analyses had notable strengths, including focusing on a particular stroke sub type (ischemic stroke) rather than group ing all strokes (including hemorrhagic strokes) together. Ischemic stroke is more likely to be due to atherosclerosis than is hemorrhagic stroke, so patients with ische mic stroke may stand to benefit more from a statin agent. Conversely, the finding of an increased risk of hemorrhagic stroke in the SPARCL trial raises concerns over safety in patients with primary hemor rhages. 5 The possible protective effect of statin treatment on functional recovery after stroke may differ depending on the cause of stroke, as Biffi et al. found in their study. 4 Additional strengths of the analyses were the large sample size and the appropriately cautious interpretation of the results in light of the publication bias.
A possible limitation of the study is presented by the protective effect of statins against recurrent stroke, which might explain some of the apparent effect on functional outcomes. Moreover, the use of statins before a stroke is not random, and unmeasured confounders in the studies (such as 'clinical nihilism' whereby patients who are deemed at high risk of a poor outcome are not prescribed statins) could be associated with both treatment and functional outcomes, leading to the erroneous conclusion of an association.
Several questions remain unanswered, the most important of which is whether patients would benefit from administration of statins in the acute setting following an ischemic stroke. Unfortunately, this question cannot be answered on the basis of the current study. In the studies included in the meta-analysis, the outcomes and inclusion criteria were heterogeneous, making comparison of the studies difficult. For example, some studies defined a good outcome as a modified Rankin Scale score of 0-2, whereas others used a score of 0-4 or another functional outcome scale. The choice of the outcome could markedly affect whether a treatment is found to be helpful.
Furthermore, each study included a dif ferent time frame for the outcome, ranging from 7-90 days after stroke.
The analysis by Biffi et al. was limited to efficacy, and did not comment on safety outcomes or whether patients who receive intravenous tissue plasminogen activator can also be given statins; this may not be a trivial point as there is reason to suspect that these agents could increase the risk of hemorrhage after stroke. 5, 6 Only one report, however, has documented an increased risk of hemorrhage after intra-arterial thrombolysis, 7 whereas most other studies have documented no increased risk of hemorrhage and an excellent safety profile. 8 The appropriate dose and route of administration of statin therapy in the context of acute ischemic stroke remains largely unexplored. 9 Recent pilot human trials have found that shortterm administration of statins at currently unapproved high doses is probably safe, and this strategy is being further investigated in ongoing studies. 10 The findings by Biffi et 
